New glaucoma treatment could overcome non-compliance

Article

An angiostatic cortisene, Anercortave Acetate (AA), may prove to be the first treatment modality for open-angle glaucoma, which only needs to be administered every three months.

An angiostatic cortisene, Anercortave Acetate (AA), may prove to be the first treatment modality for open-angle glaucoma, which only needs to be administered every three months.

Initially designed by Alcon and in phase II/III of clinical testing, it was originally intended to treat advanced macular degeneration. Following poor results an attempt was made to use it to treat dry macular degeneration, which also proved futile. However, it may now have a use in glaucoma to reduce IOP in patients.

The drug is injected beneath the conjunctiva, near the front of the eye. According to Alcon, initial proof-of-concept clinical studies demonstrated that AA has the potential for providing IOP reductions for three months or more following a single injection.

A small case study series included a total of eight eyes of seven subjects with medically uncontrolled IOP following intravitreal or sub-Tenon injections of triamcinolone acetonide. According to the study, published in Archives of Ophthalmology Vol. 127 No.2 in February 2009, the subjects received an 0.8 mL anterior juxtascleral depot of 3% AA solution (24 mg) under topical anaesthesia. IOP was then monitored weekly during month 1 and then monthly onwards for a minimum of a year. Initial results have demonstrated that AA is very effective in reversing steroid induced ocular hypertension.

Patient compliance is one of the biggest challenges facing the management of glaucoma. If successful, this form of three monthly delivery system versus drops required on a daily basis has the potential to overcome non-compliance on a huge scale.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.